Nature Cancer – Trumpp and colleagues develop a method to obtain long-term circulating tumor cell-derived organoids from individuals with metastatic breast cancer and identify the neuregulin…
Venetoclax-based treatment was associated with poorer outcomes CLL previously treated with a BTK inhibitor and naive to chemotherapy.
Communications Biology – This study describes a method for in situ recruitment of relevant cells and extracellular matrix using a novel acellular scaffold to produce…
During the 66th ASH Annual Meeting and Exposition, Mehta P. presented results from a post-hoc analysis of the UK NCRI AML19 trial evaluating the efficacy…
Enrique Ocio, MD, PhD, Marquis of Valdecilla University Hospital, Santander, Spain, comments on a pilot study within a larger Phase Ib study (NCT02513186) of isatuximab,…
Abstract. Cancer is a complex disease in which several molecular and cellular pathways converge to foster the tumoral phenotype. Notably, in the latest iteration of…
Experts at the 2024 San Antonio Breast Cancer Symposium discussed knowledge gaps in understanding how best to use ribociclib in treating patients with early breast…
The FDA has approved remestemcel-L-rknd for pediatric steroid-refractory acute graft-vs-host disease.
Submission Deadline: February 15, 2025 Cardio-oncology historically has focused on the cardiotoxic effects of cancer therapies; however, as our field continues to evolve, there is…
The PACIFIC-5 study has met its primary end point of improved PFS with consolidation durvalumab after CRT in select unresectable stage III NSCLC.
Johnson & Johnson has submitted a type II variation application to the EMA seeking the approval of ibrutinib plus R-CHOP in ASCT-eligible frontline MCL.
